Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis
Abstract
Prediction of future hepatocellular carcinoma (HCC) risk in the sizable chronic liver disease population is an urgent unmet need to enable regular HCC screening for early detection. Germline deoxyribonucleic acid polymorphisms likely represent etiology-specific host factors that determine HCC susceptibility, including single nucleotide polymorphisms in EGF, IFNL3, MICA, and TLL1 in hepatitis C with or without active viral infection, and PNPLA3, TM6SF2, and MBOAT7 in metabolic liver diseases. Transcriptome-based prognostic liver signature in diseased liver tissue has been associated with long-term HCC risk in viral and metabolic etiologies. Transcriptomic signatures of hepatic injury and specific cell type such as aggregated lymphocytes also predict HCC development. Circulating factors such as proteins and their chemical modification, nucleotides, and metabolites may serve for less-invasive assessment of short- or long-term HCC risk. These biomarkers will enable individual HCC risk-based personalized clinical management for cost-effective early HCC detection and improvement of patient survival.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 25, 2019
- Source ID
- 10.1055/s-0039-1681031
Entities
People
- Naoto Fujiwara
- Yujin Hoshida
Organizations
- Cancer Prevention and Research Institute of Texas
- European Commission
- Irma T. Hirschl Trust
- Uehara Memorial Foundation
- United States Department of Defense
- University of Texas at Austin
- University of Tokyo